ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2025
Predictors of mortality and progression from colonization to Stenotrophomonas maltophilia bloodstream infection in hematologic disorders: a single-center retrospective study.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundStenotrophomonas maltophilia (S. maltophilia) is an emerging multidrug-resistant pathogen that causes severe infections, particularly in immunocompromised patients. The bloodstream infection (BSI) of S. maltophilia is associated with high mortality rates, especially in patients with hematologic disorders. This study aimed to analyze the clinical characteristics and risk factors of S. maltophilia BSI in patients with hematologic disorders.
methodsWe conducted a single-center retrospective study of 107 patients with hematologic disorders (stratified into colonization [n = 41], colonization-to-BSI [n = 37], and primary BSI [n = 29] cohorts) at Hematology Hospital, Chinese Academy of Medical Sciences between January 2021 and September 2024. Data on demographic characteristics, clinical features, laboratory results, treatment regimens, and outcomes were collected from electronic medical records. Blood cultures were performed using the BD BACTEC™ FX system, and bacterial identification was confirmed by MALDI-TOF MS. Antimicrobial susceptibility testing was conducted by the Vitek 2 Compact system. Statistical analyses, including Cox regression and logistic regression, were performed to identify risk factors for mortality.
resultsThe 30-day mortality rate was 34.8%. Independent risk factors for mortality included prolonged neutropenia (> 1 month) (HR = 1.57, p = 0.04), shock (HR = 2.44, p < 0.01), and ceftazidime resistance (HR = 1.95, p = 0.03). Polymicrobial infections were prevalent (84.8%), and inappropriate initial antibiotic therapy occurred in 42.4% of cases. Progression from colonization to BSI was associated with neutropenia (OR = 6.85, p < 0.001), immunosuppressor use (OR = 7.20, p < 0.001), elevated CRP (> 100 mg/L, OR = 4.11, p = 0.001), and inappropriate antibiotic therapy (OR = 2.98, p = 0.039). A predictive model integrating these factors demonstrated strong performance (AUC = 0.89, 95% CI: 0.82-0.96).
conclusionS. maltophilia BSI is associated with high mortality, driven by host immunosuppression, antibiotic resistance, and delayed targeted therapy. The progression from colonization to BSI is strongly influenced by neutropenia, immunosuppressor, inflammatory markers, and inappropriate antibiotic use. These findings underscore the need for early risk stratification, and susceptibility-guided therapy in high-risk settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.